Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Read now
Weili Xue, Weiming Li, Tiantian Zhang, Zhaoming Li, Yingjun Wang, Yajuan Qiu, Yuanyuan Wang, Changying Chen, Dongjun Fu & Mingzhi Zhang. (2019) Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway. OncoTargets and Therapy 12, pages 2079-2088.
Read now
Read now
Heying Zhang, Juan Zeng, Yongqiang Tan, Lin Lu, Cheng Sun, Yusi Liang, Huawei Zou, Xianghong Yang & Yonggang Tan. (2018) Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers. OncoTargets and Therapy 11, pages 5811-5819.
Read now
Read now
Articles from other publishers (100)
Kohei Takei, Toshiki Kijima, Naoya Okubo, Ryo Kurashina, Hidetoshi Kokubun, Toshitaka Uematsu, Hironori Betsunoh, Masahiro Yashi & Takao Kamai. (2023) Association between Immune Checkpoint Inhibitor Treatment Outcomes and Body Composition Factors in Metastatic Renal Cell Carcinoma Patients. Cancers 15:23, pages 5591.
Crossref
Crossref
Karolina Aleksandrowicz, Dominika Hempel, Barbara Polityńska, Anna M. Wojtukiewicz, Kenneth V. Honn, Dean G. Tang & Marek Z. Wojtukiewicz. (2023) The Complex Role of Thrombin in Cancer and Metastasis: Focus on Interactions with the Immune System. Seminars in Thrombosis and Hemostasis.
Crossref
Crossref
Weiyuan Wang, Melanie Cristina Lopez McDonald, Christine Kim, Mirielle Ma, Zetao (Tommy) Pan, Charlotte Kaufmann & David A. Frank. (2023) The complementary roles of STAT3 and STAT1 in cancer biology: insights into tumor pathogenesis and therapeutic strategies. Frontiers in Immunology 14.
Crossref
Crossref
Yuyan Xie, Yang Zhou, Jiale Wang, Lijuan Du, Yuanyuan Ren & Fang Liu. (2023) Ferroptosis, autophagy, tumor and immunity. Heliyon 9:9, pages e19799.
Crossref
Crossref
Manisha Nigam, Abhay Prakash Mishra, Vishal Kumar Deb, Deen Bandhu Dimri, Vinod Tiwari, Simona Gabriela Bungau, Alexa Florina Bungau & Andrei-Flavius Radu. (2023) Evaluation of the association of chronic inflammation and cancer: Insights and implications. Biomedicine & Pharmacotherapy 164, pages 115015.
Crossref
Crossref
Huilan Zheng, Gang Wang, Ming Liu & Hongbin Cheng. (2023) Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review. Frontiers in Oncology 13.
Crossref
Crossref
Miles Piper, Harriet Kluger, Eytan Ruppin & Siwen Hu-Lieskovan. (2023) Immune Resistance Mechanisms and the Road to Personalized Immunotherapy. American Society of Clinical Oncology Educational Book:43.
Crossref
Crossref
Rik J. Verheijden, Mick J. M. van Eijs, Anne M. May, Femke van Wijk & Karijn P. M. Suijkerbuijk. (2023) Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. npj Precision Oncology 7:1.
Crossref
Crossref
Yidi Qu, Hongxin Yang, Siyu Li, Lanzhou Li, Yu Li & Di Wang. (2023) The involvement of Th1 cell differentiation in the anti-tumor effect of purified polysaccharide from Sanghuangporus vaninii in colorectal cancer via multi-omics analysis. International Journal of Biological Macromolecules 237, pages 123927.
Crossref
Crossref
Zhengfei He, Xiaochun Zhang, Shanshan Wang, Xiaojun Dai, Qingying Wang, Qingyun Lu, Haiyan Lu, Yongjian Wu, Hui Wang, Xuemei Wang, Haibo Wang & Yanqing Liu. (2023) The predictive value of prognosis and therapeutic response for STAT family in pancreatic cancer. Heliyon 9:5, pages e16150.
Crossref
Crossref
Heng‐Chung Kung & Jun Yu. (2023) Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study. MedComm 4:2.
Crossref
Crossref
Wenhui Liu, Zhiying Luo, Yiping Liu & Bao Sun. (2023) Current landscape and tailored management of immune-related adverse events. Frontiers in Pharmacology 14.
Crossref
Crossref
Dakota B. Poschel, Mercy Kehinde-Ige, John D. Klement, Dafeng Yang, Alyssa D. Merting, Natasha M. Savage, Huidong Shi & Kebin Liu. (2023) IRF8 Regulates Intrinsic Ferroptosis through Repressing p53 Expression to Maintain Tumor Cell Sensitivity to Cytotoxic T Lymphocytes. Cells 12:2, pages 310.
Crossref
Crossref
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi & Keywan Mortezaee. (2022) Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 156, pages 113906.
Crossref
Crossref
Walid Al-Akkad, Pilar Acedo, Maria-Giovanna Vilia, Luca Frenguelli, Alexander Ney, Irene Rodriguez-Hernandez, Peter L. Labib, Domenico Tamburrino, Gabriele Spoletini, Andrew R. Hall, Simone Canestrari, Anna Osnato, Jose Garcia-Bernardo, Leinal Sejour, Vessela Vassileva, Ioannis S. Vlachos, Giuseppe Fusai, Tu Vinh Luong, Steven R. Whittaker, Stephen P. Pereira, Ludovic Vallier, Massimo Pinzani, Krista Rombouts & Giuseppe Mazza. (2022) Tissue-Specific Human Extracellular Matrix Scaffolds Promote Pancreatic Tumour Progression and Chemotherapy Resistance. Cells 11:22, pages 3652.
Crossref
Crossref
Julia E Lefler, Catherine B MarElia-Bennett, Katie A Thies, Blake E HildrethIIIIII, Sudarshana M Sharma, Jason R Pitarresi, Lu Han, Caroline Everett, Christopher Koivisto, Maria C Cuitino, Cynthia D Timmers, Elizabeth O’Quinn, Melodie Parrish, Martin J Romeo, Amanda J Linke, G Aaron Hobbs, Gustavo Leone, Denis C Guttridge, Teresa A Zimmers, Gregory B Lesinski & Michael C Ostrowski. (2022) STAT3 in tumor fibroblasts promotes an immunosuppressive microenvironment in pancreatic cancer. Life Science Alliance 5:11, pages e202201460.
Crossref
Crossref
Zoya Qureshy, Hua Li, Yan Zeng, Jose Rivera, Ning Cheng, Christopher N. Peterson, Mi-Ok Kim, William R. Ryan, Patrick K. Ha, Julie E. Bauman, Steven J. Wang, Steven R. Long, Daniel E. Johnson & Jennifer R. Grandis. (2022) STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer. Clinical Cancer Research 28:21, pages 4737-4746.
Crossref
Crossref
Ozgur Kazan, Gozde Kir, Meftun Culpan, Gozde Ecem Cecikoglu, Gokhan Atis & Asif Yildirim. (2022)
The association between
PI3K
,
JAK
/
STAT
pathways with the
PDL
‐1 expression in prostate cancer
. Andrologia 54:10.
Crossref
Crossref
Kyung-Soo Chun, Do-Hee Kim, Pawan Kumar Raut & Young-Joon Surh. (2022) Anticancer natural products targeting immune checkpoint protein network. Seminars in Cancer Biology 86, pages 1008-1032.
Crossref
Crossref
Xin Li, Wenkai Jiang, Shi Dong, Wancheng Li, Weixiong Zhu & Wence Zhou. (2022) STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 12:10, pages 1450.
Crossref
Crossref
Igor Radanovic, Naomi Klarenbeek, Robert Rissmann, Geert Jan Groeneveld, Emilie M. J. van Brummelen, Matthijs Moerland & Jacobus J. Bosch. (2022) Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds. Frontiers in Oncology 12.
Crossref
Crossref
Yue Zhao, Zhengzheng Ji, Jiasong Li, Shasha Zhang, Chensi Wu, Ruixing Zhang & Zhanjun Guo. (2022) Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients. Frontiers in Oncology 12.
Crossref
Crossref
Muhammad Hussnain Siddique, Rahat Andleeb, Asma Ashraf, Muhammad Zubair, M. Fakhar-e-Alam, Sumreen Hayat, Saima Muzammil, M. Atif, Sulman Shafeeq & Muhammad Afzal. (2022) Integration of in silico and in vitro approaches to evaluate antioxidant and anticancer properties of Tribulus terrestris extracts. Arabian Journal of Chemistry 15:8, pages 103984.
Crossref
Crossref
James A. McCubrey, Li V. Yang, Stephen L. Abrams, Linda S. Steelman, Matilde Y. Follo, Lucio Cocco, Stefano Ratti, Alberto M. Martelli, Giuseppa Augello & Melchiorre Cervello. (2022) Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells 11:14, pages 2155.
Crossref
Crossref
Eric T. Alexander & Susan K. Gilmour. (2022) Immunomodulatory role of thrombin in cancer progression. Molecular Carcinogenesis 61:6, pages 527-536.
Crossref
Crossref
Wynne Sim, Wei-Meng Lim, Ling-Wei Hii, Chee-Onn Leong & Chun-Wai Mai. (2022) Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases. World Journal of Gastroenterology 28:18, pages 1934-1945.
Crossref
Crossref
Timothy J. Barley, Parker R. Murphy, Xiantao Wang, Bridget A. Bowman, Justin M. Mormol, Carli E. Mager, Sean G. Kirk, Charles J. Cash, Sarah C. Linn, Xiaomei Meng, Leif D. Nelin, Bernadette Chen, Markus Hafner, Jian Zhang & Yusen Liu. (2022) Mitogen-activated protein kinase phosphatase-1 controls PD-L1 expression by regulating type I interferon during systemic Escherichia coli infection. Journal of Biological Chemistry 298:5, pages 101938.
Crossref
Crossref
Yuan Jiang, Qiankun Ji, Xiaoyan Long, Peng Wang, Zewei Tu, Xian Zhang, Xingen Zhu, Kai Huang & Jingying Li. (2022) CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma. Frontiers in Immunology 13.
Crossref
Crossref
Maria A. Papadaki, Alexia Monastirioti, Christina A. Apostolopoulou, Despoina Aggouraki, Chara Papadaki, Kleita Michaelidou, Maria Vassilakopoulou, Katerina Alexakou, Dimitrios Mavroudis & Sofia Agelaki. (2022) TLR4 and pSTAT3 Expression on Circulating Tumor Cells (CTCs) and Immune Cells in the Peripheral Blood of Breast Cancer Patients: Prognostic Implications. Cancers 14:4, pages 1053.
Crossref
Crossref
Lifang Zhao, Hongyan Zhang, Xueqing Liu, Shan Xue, Dongfang Chen, Jing Zou & Handong Jiang. (2022) TGR5 deficiency activates antitumor immunity in non-small cell lung cancer via restraining M2 macrophage polarization. Acta Pharmaceutica Sinica B 12:2, pages 787-800.
Crossref
Crossref
Weina Yu, Fengsen Liu, Qingyang Lei, Peng Wu, Li Yang & Yi Zhang. (2022) Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis. Frontiers in Oncology 11.
Crossref
Crossref
Meagan-Helen Henderson Berg, Sonia Victoria del Rincón & Wilson H Miller. (2022) Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. Journal for ImmunoTherapy of Cancer 10:1, pages e003551.
Crossref
Crossref
A-min Wang, Ru Qiu, Duo Zhang & Xiao-yan Zhao. (2022) Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation. Translational Oncology 15:1, pages 101288.
Crossref
Crossref
Mengting Chen, Renske Linstra & Marcel A.T.M. van Vugt. (2022) Genomic instability, inflammatory signaling and response to cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188661.
Crossref
Crossref
Matthias Theobald, Peter Brossart & Barbara Seliger. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
15
.
Zhilin Zhang, Huan Zhang, Tian Liu, Tian Chen, Daorong Wang & Dong Tang. (2021) Heterogeneous Pancreatic Stellate Cells Are Powerful Contributors to the Malignant Progression of Pancreatic Cancer. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Zhi Zong, Yujun Wei, Jiang Ren, Long Zhang & Fangfang Zhou. (2021) The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer 20:1.
Crossref
Crossref
Jie Li, Chao Xu, Yueyue Lu, Yan Zhang & Xiaoping Tan. (2021)
Mesoporous TiO
2
Nanaoparticles Inhibits Malignant Pancreatic Cancer Cells Through STAT Pathway
. Science of Advanced Materials 13:9, pages 1716-1723.
Crossref
Crossref
Juncheng Wang, Yuxi Tian, Gangcai Zhu, Zhexuan Li, Zhisheng Wu, Guifang Wei, Liming Zhuang, Zhonghua Li, Xun Chen, Xin Zhang, Jinyang Zheng & Gengming Cai. (2021) Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma. International Immunopharmacology 97, pages 107817.
Crossref
Crossref
Alessandro Di Federico, Valentina Tateo, Claudia Parisi, Francesca Formica, Riccardo Carloni, Giorgio Frega, Alessandro Rizzo, Dalia Ricci, Mariacristina Di Marco, Andrea Palloni & Giovanni Brandi. (2021) Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. Pharmaceuticals 14:7, pages 677.
Crossref
Crossref
Shun Wang, Yan Zheng, Feng Yang, Le Zhu, Xiao-Qiang Zhu, Zhe-Fang Wang, Xiao-Lin Wu, Cheng-Hui Zhou, Jia-Yan Yan, Bei-Yuan Hu, Bo Kong, De-Liang Fu, Christiane Bruns, Yue Zhao, Lun-Xiu Qin & Qiong-Zhu Dong. (2021) The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Chunwan Lu, Zhuoqi Liu, John D Klement, Dafeng Yang, Alyssa D Merting, Dakota Poschel, Thomas Albers, Jennifer L Waller, Huidong Shi & Kebin Liu. (2021) WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. Journal for ImmunoTherapy of Cancer 9:7, pages e002624.
Crossref
Crossref
Ihsan Ekin Demir, Carmen Mota Reyes, Elke Demir & Helmut Friess. 2021. Clinical Pancreatology for Practising Gastroenterologists and Surgeons. Clinical Pancreatology for Practising Gastroenterologists and Surgeons
404
408
.
Sarah Peisl, Claudia Mellenthin, Lucie Vignot, Carmen Gonelle-Gispert, Leo Bühler & Bernhard Egger. (2021) Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature. PLOS ONE 16:6, pages e0252397.
Crossref
Crossref
Ming Wang, Xudong Ma, Kang Zhou, Huijuan Mao, Jiachun Liu, Xuqiong Xiong, Xiaoyin Zhao, Suresh Narva, Yoshimasa Tanaka, Yanling Wu, Chuanxin Guo, Hiroshi Sugiyama & Wen Zhang. (2021) Discovery of Pyrrole-imidazole Polyamides as PD-L1 Expression Inhibitors and Their Anticancer Activity via Immune and Nonimmune Pathways. Journal of Medicinal Chemistry 64:9, pages 6021-6036.
Crossref
Crossref
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah & Alex Friedlaender. (2021) Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treatment Reviews 96, pages 102179.
Crossref
Crossref
Seyed Hossein Kiaie, Mohammad Javad Sanaei, Masoud Heshmati, Zahra Asadzadeh, Iman Azimi, Saleh Hadidi, Reza Jafari & Behzad Baradaran. (2021) Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharmaceutica Sinica B 11:5, pages 1083-1097.
Crossref
Crossref
Katerina Chatzidionysiou, Matina Liapi, Georgios Tsakonas, Iva Gunnarsson & Anca Catrina. (2020) Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?. Clinical Rheumatology 40:5, pages 1687-1695.
Crossref
Crossref
Reham Ajina, Zoe X. Malchiodi, Allison A. Fitzgerald, Annie Zuo, Shangzi Wang, Maha Moussa, Connor J. Cooper, Yue Shen, Quentin R. Johnson, Jerry M. Parks, Jeremy C. Smith, Marta Catalfamo, Elana J. Fertig, Sandra A. Jablonski & Louis M. Weiner. (2021) Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. Cancer Immunology Research 9:4, pages 386-400.
Crossref
Crossref
Zhiyan Ruan, Minhua Liang, Ling Shang, Manxiang Lai, Xiangliang Deng & Xinguo Su. (2021) Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-κB/STAT3 and NF-κB/CSN5 signaling pathways. Pancreatology 21:3, pages 630-641.
Crossref
Crossref
Darya Javadrashid, Amir Baghbanzadeh, Nima Hemmat, Khalil Hajiasgharzadeh, Niloufar Sadat Nourbakhsh, Ziba Lotfi & Behzad Baradaran. (2021) Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?. Immunology Letters 232, pages 48-59.
Crossref
Crossref
Toshio Hirano. (2021) IL-6 in inflammation, autoimmunity and cancer. International Immunology 33:3, pages 127-148.
Crossref
Crossref
Hannah Giles & Guy Pratt. (2020) Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment. British Journal of Haematology 192:3, pages 420-422.
Crossref
Crossref
Bin Pan, Longmei Shang, Cong Liu, Jun Gao, Fan Zhang, Mengdi Xu, Lingling Li, Zengtian Sun, Zhenyu Li & Kailin Xu. (2021) PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice. American Journal of Transplantation 21:2, pages 503-514.
Crossref
Crossref
Peng Zhang, Yanfei Zhang, Liang Wang & Weihua Lou. (2021) Tumor-regulated macrophage type 2 differentiation promotes immunosuppression in laryngeal squamous cell carcinoma. Life Sciences 267, pages 118798.
Crossref
Crossref
Jinlian Cai, Hong Deng, Linlin Luo, Luxia You, Huitian Liao & Yan Zheng. (2020) Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma. Aging 13:2, pages 2073-2088.
Crossref
Crossref
Eleftheria LamprianidouChryssoula KordellaAnastasiya KazachenkaEmmanouela ZouliaElsa Bernard, Anastasia FiliaStamatia LaidouPanayiotis GarantziotisTheodoros P. VassilakopoulosSotirios G. Papageorgiou, Vassiliki PappaAthanasios G. GalanopoulosNora ViniouEvangelia NakouLydia Kalafati, Anastasia ChatzidimitriouGeorge Kassiotis, Elli PapaemmanuilIoannis Mitroulis & Ioannis Kotsianidis. (2021) Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3− T cells represents a potential antitumor mechanism of azacitidine. Blood Advances 5:1, pages 129-142.
Crossref
Crossref
Teng Li, Han Wang, Jiachen Xu, Chengcheng Li, Yudong Zhang, Guoqiang Wang, Yutao Liu, Shangli Cai, Wenfeng Fang, Junling Li & Zhijie Wang. (2021) TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592110384.
Crossref
Crossref
Sen Yu, Chunyu Zhang & Ke-Ping Xie. (2021) Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188461.
Crossref
Crossref
Jiang-Feng Shen, Jin-Feng Ge, Shi-Ying Zheng & Dong Jiang. (2021) Integrative analysis of differential circular RNA and long non-coding RNA profiles and associated competing endogenous RNA networks in esophageal squamous cell carcinoma. Functional & Integrative Genomics 21:1, pages 125-138.
Crossref
Crossref
Hao Zhang, Changhao Zhu, Zhiwei He, Shiyu Chen, Lin Li & Chengyi Sun. (2020) LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Sailan Zou, Qiyu Tong, Bowen Liu, Wei Huang, Yan Tian & Xianghui Fu. (2020) Targeting STAT3 in Cancer Immunotherapy. Molecular Cancer 19:1.
Crossref
Crossref
Andrew Cannon, Christopher M. Thompson, H. Carlo Maurer, Pranita Atri, Rakesh Bhatia, Sean West, Dario Ghersi, Kenneth P. Olive, Sushil Kumar & Surinder K. Batra. (2020) CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research 26:22, pages 6051-6063.
Crossref
Crossref
Reham Ajina, David J. Zahavi, Yong-Wei Zhang & Louis M. Weiner. (2020) Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. Seminars in Cancer Biology 65, pages 28-37.
Crossref
Crossref
Yoshie Kobayashi, Seung-Oe Lim & Hirohito Yamaguchi. (2020) Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. Seminars in Cancer Biology 65, pages 51-64.
Crossref
Crossref
Rui Hu, Qiuju Han & Jian Zhang. (2020) STAT3: A key signaling molecule for converting cold to hot tumors. Cancer Letters 489, pages 29-40.
Crossref
Crossref
Nirvana Kalantari Khandani, Atefeh Ghahremanloo & Seyed Isaac Hashemy. (2020) Role of tumor microenvironment in the regulation of PD‐L1: A novel role in resistance to cancer immunotherapy. Journal of Cellular Physiology 235:10, pages 6496-6506.
Crossref
Crossref
Christopher Gromisch, Motaz Qadan, Mariana Albuquerque Machado, Kebin Liu, Yolonda Colson & Mark W. Grinstaff. (2020) Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Research 80:16, pages 3179-3192.
Crossref
Crossref
Ning Kang, Mark Eccleston, Pier-Luc Clermont, Maryam Latarani, David Kingsley Male, Yuzhuo Wang & Francesco Crea. (2020) EZH2 inhibition: a promising strategy to prevent cancer immune editing. Epigenomics 12:16, pages 1457-1476.
Crossref
Crossref
Filipe Martins & Michel Obeid. (2020) Personalized treatment of immune-related adverse events — balance is required. Nature Reviews Clinical Oncology 17:8, pages 517-517.
Crossref
Crossref
Khashayar Esfahani, Arielle Elkrief, Cassandra Calabrese, Réjean Lapointe, Marie Hudson, Bertrand Routy, Wilson H. MillerJrJr & Leonard Calabrese. (2020) Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology 17:8, pages 504-515.
Crossref
Crossref
Bakiye Goker Bagca & Cigir Biray Avci. (2020) The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19. Cytokine & Growth Factor Reviews 54, pages 51-61.
Crossref
Crossref
Annelisa M. Cornel, Iris L. Mimpen & Stefan Nierkens. (2020) MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers 12:7, pages 1760.
Crossref
Crossref
Julian Mohrherr, Iris Z. Uras, Herwig P. Moll & Emilio Casanova. (2020) STAT3: Versatile Functions in Non-Small Cell Lung Cancer. Cancers 12:5, pages 1107.
Crossref
Crossref
Xuanyi Wang, Zixuan Chai, Yinghong Li, Fei Long, Youjin Hao, Guizhi Pan, Mingwei Liu & Bo Li. (2020) Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis. Genes 11:4, pages 435.
Crossref
Crossref
Yannick Verhoeven, Sam Tilborghs, Julie Jacobs, Jorrit De Waele, Delphine Quatannens, Christophe Deben, Hans Prenen, Patrick Pauwels, Xuan Bich Trinh, An Wouters, Evelien L.J. Smits, Filip Lardon & Peter A. van Dam. (2020) The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology 60, pages 41-56.
Crossref
Crossref
Hui-Feng Gao, Chien-Shan Cheng, Jian Tang, Ye Li, Hao Chen, Zhi-Qiang Meng, Zhen Chen & Lian-Yu Chen. (2020) CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Aging 12:1, pages 502-517.
Crossref
Crossref
Fan Luo, Min Luo, Qi-Xiang Rong, Hong Zhang, Zhen Chen, Fang Wang, Hong-Yun Zhao & Li-Wu Fu. (2019) Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Chin-King Looi, Felicia Fei-Lei Chung, Chee-Onn Leong, Shew-Fung Wong, Rozita Rosli & Chun-Wai Mai. (2019) Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Ying Fan, Shu Li, Xiaoyan Ding, Jian Yue, Jun Jiang, Hong Zhao, Rui Hao, Weiliang Qiu, Kezhen Liu, Ying Li, Shengdian Wang, Limin Zheng, Bin Ye, Kun Meng & Binghe Xu. (2019) First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. BMC Cancer 19:1.
Crossref
Crossref
Gulzar Ahmad, Gerardo G. Mackenzie, James Egan & Mansoor M. Amiji. (2019) DHA-SBT-1214 Taxoid Nanoemulsion and Anti–PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Molecular Cancer Therapeutics 18:11, pages 1961-1972.
Crossref
Crossref
Manish R. Patel, Alexander Dash, Blake A. Jacobson, Yan Ji, Daniel Baumann, Kareem Ismail & Robert A. Kratzke. (2019) JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models. Cancer Gene Therapy 26:11-12, pages 411-418.
Crossref
Crossref
Ioannis Zerdes, Majken Wallerius, Emmanouil Sifakis, Tatjana Wallmann, Stina Betts, Margarita Bartish, Nikolaos Tsesmetzis, Nicholas Tobin, Christos Coucoravas, Jonas Bergh, George Rassidakis, Charlotte Rolny & Theodoros Foukakis. (2019) STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers 11:10, pages 1479.
Crossref
Crossref
Zhengkui Zhang, Jisong Li, Huahu Guo, Feng Wang, Ling Ma, Chong Du, Yazhou Wang, Qi Wang, Marko Kornmann, Xiaodong Tian & Yinmo Yang. (2019) BRM transcriptionally regulates miR-302a-3p to target SOCS5/STAT3 signaling axis to potentiate pancreatic cancer metastasis. Cancer Letters 449, pages 215-225.
Crossref
Crossref
Jiahong Jiang, Huaixiang Zhou, Chao Ni, Xiaoge Hu, Yiping Mou, Dongsheng Huang & Liu Yang. (2019) Immunotherapy in pancreatic cancer: New hope or mission impossible?. Cancer Letters 445, pages 57-64.
Crossref
Crossref
Michel Ducreux, Thomas Seufferlein, Jean-Luc Van Laethem, Pierre Laurent-Puig, Cristina Smolenschi, David Malka, Valérie Boige, Antoine Hollebecque & Thierry Conroy. (2019) Systemic treatment of pancreatic cancer revisited. Seminars in Oncology 46:1, pages 28-38.
Crossref
Crossref
Dounia Chraa, Asmaa Naim, Daniel Olive & Abdallah Badou. (2019) T lymphocyte subsets in cancer immunity: Friends or foes. Journal of Leukocyte Biology 105:2, pages 243-255.
Crossref
Crossref
Chunguo Cui, Bo Yu, Qi Jiang, Xingfang Li, Kaiyao Shi & Zecheng Yang. (2018)
The roles of
PD
‐1/
PD
‐L1 and its signalling pathway in gastrointestinal tract cancers
. Clinical and Experimental Pharmacology and Physiology 46:1, pages 3-10.
Crossref
Crossref
Christos Fountzilas, Sunyoung S. Lee, Renuka V. Iyer & Patrick M. Boland. 2019. Immune Checkpoint Inhibitors in Cancer. Immune Checkpoint Inhibitors in Cancer
77
101
.
Anastasiya Yakovenko, Miles Cameron & Jose Gilberto Trevino. (2018) Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World Journal of Gastrointestinal Surgery 10:9, pages 95-106.
Crossref
Crossref
Juliane Friedrich, Lisanne Heim, Denis I. Trufa, Horia Sirbu, Ralf J. Rieker, Mircea T. Chiriac & Susetta Finotto. (2018) STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFα mediated immune responses in a model of NSCLC. Oncotarget 9:98, pages 37157-37172.
Crossref
Crossref
Jun Gong, Andrew Hendifar, Richard Tuli, Jeremy Chuang, May Cho, Vincent Chung, Daneng Li & Ravi Salgia. (2018) Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade. Clinical and Translational Medicine 7:1.
Crossref
Crossref
Chunwan Lu, Dafeng Yang, Maria E. Sabbatini, Aaron H. Colby, Mark W. Grinstaff, Nicholas H. Oberlies, Cedric Pearce & Kebin Liu. (2018) Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells. BMC Cancer 18:1.
Crossref
Crossref
Mohammed G. Ghonime & Kevin A. Cassady. (2018) Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunology Research 6:12, pages 1499-1510.
Crossref
Crossref
Wei-fa Yang, May C.M. Wong, Peter J. Thomson, Kar-Yan Li & Yu-xiong Su. (2018) The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncology 86, pages 81-90.
Crossref
Crossref
Daniel E. Johnson, Rachel A. O'Keefe & Jennifer R. Grandis. (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology 15:4, pages 234-248.
Crossref
Crossref
Anthousa Kythreotou, Abdul Siddique, Francesco A Mauri, Mark Bower & David J Pinato. (2018) PD-L1. Journal of Clinical Pathology 71:3, pages 189-194.
Crossref
Crossref
Neus Martinez-Bosch, Judith Vinaixa & Pilar Navarro. (2018) Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers 10:1, pages 6.
Crossref
Crossref
Ilaria Attili, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Jillian Bracht, Jordi Codony-Servat, Carles Codony-Servat, Masaoki Ito & Rafael Rosell. (2018) STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Advances in Medical Oncology 10, pages 175883591876374.
Crossref
Crossref
Marie Febvre-James, Valérie Lecureur, Yu Augagneur, Abdullah Mayati & Olivier Fardel. (2018) Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages. International Immunopharmacology 54, pages 354-365.
Crossref
Crossref